Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, Jacoberger-Foissac C, Wong C, Dela Cruz T, Welch M, Lerner AG, Spatola BN, Soros VB, Corbin J, Anderson AC, Effern M, Hölzel M, Robson SC, Johnston RL, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng MWL, Smyth MJ.

Cancer Discov. 2019 Dec;9(12):1754-1773. doi: 10.1158/2159-8290.CD-19-0541. Epub 2019 Nov 7.

PMID:
31699796
2.

APOBEC3G and HIV-1: strike and counterstrike.

Soros VB, Greene WC.

Curr HIV/AIDS Rep. 2007 Feb;4(1):3-9.

PMID:
17338854
4.

High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.

Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93. Epub 2006 Oct 9.

5.

APOBEC3G and HIV-1: strike and counterstrike.

Soros VB, Greene WC.

Curr Infect Dis Rep. 2006 Jun;8(4):317-23.

PMID:
16822376
6.

Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.

Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC.

Nature. 2005 May 5;435(7038):108-14. Epub 2005 Apr 13. Retraction in: Nature. 2010 Jul 8;466(7303):276.

PMID:
15829920
7.

Supplemental Content

Loading ...
Support Center